Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats.

Van Den Berge N, Ferreira N, Gram H, Mikkelsen TW, Alstrup AKO, Casadei N, Tsung-Pin P, Riess O, Nyengaard JR, Tamgüney G, Jensen PH, Borghammer P.

Acta Neuropathol. 2019 Jun 26. doi: 10.1007/s00401-019-02040-w. [Epub ahead of print]

PMID:
31254094
2.

Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.

Vicioso Y, Gram H, Beck R, Asthana A, Zhang K, Wong DP, Letterio J, Parameswaran R.

Cancer Immunol Res. 2019 Jul;7(7):1106-1119. doi: 10.1158/2326-6066.CIR-19-0058. Epub 2019 May 28.

PMID:
31138521
3.

Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.

Dörner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, Kamphausen E, Valentin MA, Simonett C, Mooney L, Hüser A, Gram H, Wagner FD, Oliver SJ.

Ann Rheum Dis. 2019 May;78(5):641-647. doi: 10.1136/annrheumdis-2018-214720. Epub 2019 Mar 2.

PMID:
30826774
4.

Stage-dependent differential effects of interleukin-1 isoforms on experimental atherosclerosis.

Vromman A, Ruvkun V, Shvartz E, Wojtkiewicz G, Santos Masson G, Tesmenitsky Y, Folco E, Gram H, Nahrendorf M, Swirski FK, Sukhova GK, Libby P.

Eur Heart J. 2019 Jan 30. doi: 10.1093/eurheartj/ehz008. [Epub ahead of print]

PMID:
30698710
5.

The long and winding road in pharmaceutical development of canakinumab from rare genetic autoinflammatory syndromes to myocardial infarction and cancer.

Gram H.

Pharmacol Res. 2019 Jan 14:104139. doi: 10.1016/j.phrs.2019.01.023. [Epub ahead of print] Review.

6.

Interleukin-1β has atheroprotective effects in advanced atherosclerotic lesions of mice.

Gomez D, Baylis RA, Durgin BG, Newman AAC, Alencar GF, Mahan S, St Hilaire C, Müller W, Waisman A, Francis SE, Pinteaux E, Randolph GJ, Gram H, Owens GK.

Nat Med. 2018 Sep;24(9):1418-1429. doi: 10.1038/s41591-018-0124-5. Epub 2018 Jul 23.

7.

Neutralization of Interleukin-1β following Diffuse Traumatic Brain Injury in the Mouse Attenuates the Loss of Mature Oligodendrocytes.

Flygt J, Ruscher K, Norberg A, Mir A, Gram H, Clausen F, Marklund N.

J Neurotrauma. 2018 Dec 1;35(23):2837-2849. doi: 10.1089/neu.2018.5660. Epub 2018 Jul 30.

8.

An Activating Janus Kinase-3 Mutation Is Associated with Cytotoxic T Lymphocyte Antigen-4-Dependent Immune Dysregulation Syndrome.

Sic H, Speletas M, Cornacchione V, Seidl M, Beibel M, Linghu B, Yang F, Sevdali E, Germenis AE, Oakeley EJ, Vangrevelinghe E, Sailer AW, Traggiai E, Gram H, Eibel H.

Front Immunol. 2017 Dec 15;8:1824. doi: 10.3389/fimmu.2017.01824. eCollection 2017.

9.

Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.

Brachat AH, Grom AA, Wulffraat N, Brunner HI, Quartier P, Brik R, McCann L, Ozdogan H, Rutkowska-Sak L, Schneider R, Gerloni V, Harel L, Terreri M, Houghton K, Joos R, Kingsbury D, Lopez-Benitez JM, Bek S, Schumacher M, Valentin MA, Gram H, Abrams K, Martini A, Lovell DJ, Nirmala NR, Ruperto N; Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).

Arthritis Res Ther. 2017 Jan 23;19(1):13. doi: 10.1186/s13075-016-1212-x.

10.

Therapeutic Administration of a Monoclonal Anti-Il-1β Antibody Protects Against Experimental Melioidosis.

Weehuizen TA, Lankelma JM, De Jong HK, De Boer OJ, Roelofs JJ, Day NP, Gram H, De Vos AF, Wiersinga WJ.

Shock. 2016 Nov;46(5):566-574.

11.

Diffuse traumatic axonal injury in mice induces complex behavioural alterations that are normalized by neutralization of interleukin-1β.

Ekmark-Lewén S, Flygt J, Fridgeirsdottir GA, Kiwanuka O, Hånell A, Meyerson BJ, Mir AK, Gram H, Lewén A, Clausen F, Hillered L, Marklund N.

Eur J Neurosci. 2016 Apr;43(8):1016-33. doi: 10.1111/ejn.13190. Epub 2016 Mar 11.

PMID:
27091435
12.

Preclinical characterization and clinical development of ILARIS(®) (canakinumab) for the treatment of autoinflammatory diseases.

Gram H.

Curr Opin Chem Biol. 2016 Jun;32:1-9. doi: 10.1016/j.cbpa.2015.12.003. Epub 2015 Dec 23. Review.

13.

Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.

Korneeva NL, Song A, Gram H, Edens MA, Rhoads RE.

J Biol Chem. 2016 Feb 12;291(7):3455-67. doi: 10.1074/jbc.M115.694190. Epub 2015 Dec 14.

14.

The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.

Rondeau JM, Ramage P, Zurini M, Gram H.

MAbs. 2015;7(6):1151-60. doi: 10.1080/19420862.2015.1081323. Epub 2015 Aug 18.

15.

Reducing Vascular Calcification by Anti-IL-1β Monoclonal Antibody in a Mouse Model of Familial Hypercholesterolemia.

Awan Z, Denis M, Roubtsova A, Essalmani R, Marcinkiewicz J, Awan A, Gram H, Seidah NG, Genest J.

Angiology. 2016 Feb;67(2):157-67. doi: 10.1177/0003319715583205. Epub 2015 Apr 22.

PMID:
25904765
16.

Biomarkers in systemic juvenile idiopathic arthritis: a comparison with biomarkers in cryopyrin-associated periodic syndromes.

Nirmala N, Grom A, Gram H.

Curr Opin Rheumatol. 2014 Sep;26(5):543-52. doi: 10.1097/BOR.0000000000000098. Review.

17.

Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R.

Parameswaran R, Lim M, Fei F, Abdel-Azim H, Arutyunyan A, Schiffer I, McLaughlin ME, Gram H, Huet H, Groffen J, Heisterkamp N.

Mol Cancer Ther. 2014 Jun;13(6):1567-77. doi: 10.1158/1535-7163.MCT-13-1023. Epub 2014 May 13.

18.

Pharmacokinetics, biocompatibility and bioavailability of a controlled release monoclonal antibody formulation.

Schweizer D, Vostiar I, Heier A, Serno T, Schoenhammer K, Jahn M, Jones S, Piequet A, Beerli C, Gram H, Goepferich A.

J Control Release. 2013 Dec 28;172(3):975-82. doi: 10.1016/j.jconrel.2013.10.010. Epub 2013 Oct 15.

PMID:
24140353
19.

Interleukin-1 mediates neuroinflammatory changes associated with diet-induced atherosclerosis.

Denes A, Drake C, Stordy J, Chamberlain J, McColl BW, Gram H, Crossman D, Francis S, Allan SM, Rothwell NJ.

J Am Heart Assoc. 2012 Jun;1(3):e002006. doi: 10.1161/JAHA.112.002006. Epub 2012 Jun 22.

20.

Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody.

Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, Roy S.

Clin Pharmacokinet. 2012 Jun 1;51(6):e1-18. doi: 10.2165/11599820-000000000-00000. Review.

21.

Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma.

Sriwanitchrak P, Viyanant V, Chaijaroenkul W, Srivatanakul P, Gram HR, Eursiddhichai V, Na-Bangchang K.

Asian Pac J Cancer Prev. 2011;12(6):1503-10.

22.

Inhibitory effects of anti-IL-1β antibody in murine AA amyloidosis mode.

Murata S, Ueda M, Tanabe Y, Kurata N, Demura N, Gram H, Tasaki M, Su Y, Jono H, Shono M, Obayashi K, Ando Y.

Amyloid. 2011 Jun;18 Suppl 1:38-9. doi: 10.3109/13506129.2011.574354013. No abstract available. Erratum in: Amyloid. 2011 Jun;18 Suppl 1:39.

PMID:
21838425
23.

Neutralization of interleukin-1β reduces cerebral edema and tissue loss and improves late cognitive outcome following traumatic brain injury in mice.

Clausen F, Hånell A, Israelsson C, Hedin J, Ebendal T, Mir AK, Gram H, Marklund N.

Eur J Neurosci. 2011 Jul;34(1):110-23. doi: 10.1111/j.1460-9568.2011.07723.x. Epub 2011 May 30.

PMID:
21623956
24.

Mnk mediates integrin α6β4-dependent eIF4E phosphorylation and translation of VEGF mRNA.

Korneeva NL, Soung YH, Kim HI, Giordano A, Rhoads RE, Gram H, Chung J.

Mol Cancer Res. 2010 Dec;8(12):1571-8. doi: 10.1158/1541-7786.MCR-10-0091. Epub 2010 Oct 21.

25.

Neutralization of interleukin-1beta modifies the inflammatory response and improves histological and cognitive outcome following traumatic brain injury in mice.

Clausen F, Hånell A, Björk M, Hillered L, Mir AK, Gram H, Marklund N.

Eur J Neurosci. 2009 Aug;30(3):385-96. doi: 10.1111/j.1460-9568.2009.06820.x. Epub 2009 Jul 15.

PMID:
19614750
26.

The critical role of kinase activity of interleukin-1 receptor-associated kinase 4 in animal models of joint inflammation.

Koziczak-Holbro M, Littlewood-Evans A, Pöllinger B, Kovarik J, Dawson J, Zenke G, Burkhart C, Müller M, Gram H.

Arthritis Rheum. 2009 Jun;60(6):1661-71. doi: 10.1002/art.24552.

27.

Insights into the roles of the inflammatory mediators IL-1, IL-18 and PGE2 in obesity and insulin resistance.

Osborn O, Gram H, Zorrilla EP, Conti B, Bartfai T.

Swiss Med Wkly. 2008 Nov 15;138(45-46):665-73. doi: /aop/smw-aop12276.

PMID:
18855149
28.

Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity.

Osborn O, Brownell SE, Sanchez-Alavez M, Salomon D, Gram H, Bartfai T.

Cytokine. 2008 Oct;44(1):141-8. doi: 10.1016/j.cyto.2008.07.004. Epub 2008 Aug 23.

29.

Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.

Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, Druker BJ, Trapp V, Fruehauf J, Gram H, Fan HY, Ong ST.

Mol Cell Biol. 2008 Oct;28(20):6496-509. doi: 10.1128/MCB.00477-08. Epub 2008 Aug 11.

30.

The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.

Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S, Burmester G, van Riel P, Diaz-Lorente M, Bruin GJ, Woodworth TG, Rordorf C, Batard Y, Wright AM, Jung T.

Arthritis Res Ther. 2008;10(3):R67. doi: 10.1186/ar2438. Epub 2008 Jun 5.

31.

Solving the IRAK-4 enigma: application of kinase-dead knock-in mice.

Koziczak-Holbro M, Joyce C, Glück A, Kinzel B, Müller M, Gram H.

Ernst Schering Found Symp Proc. 2007;(3):63-82.

PMID:
18510099
32.

IRAK-4 kinase activity-dependent and -independent regulation of lipopolysaccharide-inducible genes.

Koziczak-Holbro M, Glück A, Tschopp C, Mathison JC, Gram H.

Eur J Immunol. 2008 Mar;38(3):788-96. doi: 10.1002/eji.200737886.

33.

IRAK-4 kinase activity is required for interleukin-1 (IL-1) receptor- and toll-like receptor 7-mediated signaling and gene expression.

Koziczak-Holbro M, Joyce C, Glück A, Kinzel B, Müller M, Tschopp C, Mathison JC, Davis CN, Gram H.

J Biol Chem. 2007 May 4;282(18):13552-60. Epub 2007 Mar 2.

34.

MNK1 and MNK2 regulation in HER2-overexpressing breast cancer lines.

Chrestensen CA, Shuman JK, Eschenroeder A, Worthington M, Gram H, Sturgill TW.

J Biol Chem. 2007 Feb 16;282(7):4243-52. Epub 2006 Nov 27.

35.

A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.

Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, Breedveld FC, Dinant HJ, Legay F, Gram H, Loetscher P, Schmouder R, Woodworth T, Tak PP.

Arthritis Rheum. 2006 Aug;54(8):2387-92.

36.

Pyrazoloheteroaryls: novel p38alpha MAP kinase inhibiting scaffolds with oral activity.

Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Neumann U, Rucklin G.

Bioorg Med Chem Lett. 2006 Jan 15;16(2):262-6. Epub 2005 Oct 24.

PMID:
16249085
37.

Production of antibodies to canine IL-1beta and canine TNF to assess the role of proinflammatory cytokines.

Baggio V, Ott F, Fischer RW, Gram H, Peele J, Spreng D, Schmökel H, Jungi TW.

Vet Immunol Immunopathol. 2005 Aug 15;107(1-2):27-39.

PMID:
15982477
38.

Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1.

Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova FE, Boots AM, Gram H, Joosten LA, van den Berg WB.

Am J Pathol. 2005 Jul;167(1):141-9.

39.

Involvement of microRNA in AU-rich element-mediated mRNA instability.

Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram H, Han J.

Cell. 2005 Mar 11;120(5):623-34.

40.

SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity.

Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3601-5.

PMID:
15177483
41.

Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.

Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3595-9.

PMID:
15177482
42.

Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation.

Schuler W, Bigaud M, Brinkmann V, Di Padova F, Geisse S, Gram H, Hungerford V, Kleuser B, Kristofic C, Menninger K, Tees R, Wieczorek G, Wilt C, Wioland C, Zurini M.

Transplantation. 2004 Mar 15;77(5):717-26.

PMID:
15021835
43.

SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors.

Revesz L, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Wolf R, Zimmerlin AG.

Bioorg Med Chem Lett. 2002 Aug 19;12(16):2109-12.

PMID:
12127515
44.

MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha.

Ge B, Gram H, Di Padova F, Huang B, New L, Ulevitch RJ, Luo Y, Han J.

Science. 2002 Feb 15;295(5558):1291-4.

45.
46.

Gene suppression by tristetraprolin and release by the p38 pathway.

Zhu W, Brauchle MA, Di Padova F, Gram H, New L, Ono K, Downey JS, Han J.

Am J Physiol Lung Cell Mol Physiol. 2001 Aug;281(2):L499-508.

47.

Independent role of p38 and ERK1/2 mitogen-activated kinases in the upregulation of matrix metalloproteinase-1.

Brauchle M, Glück D, Di Padova F, Han J, Gram H.

Exp Cell Res. 2000 Jul 10;258(1):135-44.

PMID:
10912795
48.

Phosphorylation of eIF-4E on Ser 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies.

Tschopp C, Knauf U, Brauchle M, Zurini M, Ramage P, Glueck D, New L, Han J, Gram H.

Mol Cell Biol Res Commun. 2000 Apr;3(4):205-211.

PMID:
10891393
49.

SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.

Revesz L, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Zimmerlin AG.

Bioorg Med Chem Lett. 2000 Jun 5;10(11):1261-4.

PMID:
10866395
50.

Regulation of TNF expression by multiple mitogen-activated protein kinase pathways.

Zhu W, Downey JS, Gu J, Di Padova F, Gram H, Han J.

J Immunol. 2000 Jun 15;164(12):6349-58.

Supplemental Content

Support Center